FDA To Review AstraZeneca Diabetes Drug For Heart Risks
The agency asked AstraZeneca to supply it with clinical trial data in order to examine a possible link between the drugmaker's saxagliptin and heart failure. Saxagliptin is marketed as Onglyza and Kombiglyze XR.
The request stems from a study that appeared in the New England Journal...
To view the full article, register now.